General Counsel · Verona Pharma plc (VRNA)

Andrew Fisher

FY2024 is the first fiscal year CompBrief holds for Andrew Fisher as a named executive officer of Verona Pharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$10,821,932

Salary $352,557Stock awards $6,783,563

3rd of 5 named executive officers at Verona Pharma by FY2024 total.

5 named officers on file for Verona Pharma, FY2024

Andrew Fisher’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • VRNA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Verona Pharma’s whole pay program stands against its peers

  • Verona Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRNA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 18, 2025 (DEF 14A).

Free

Get Andrew Fisher’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Andrew Fisher compensation by year

Verona Pharma Summary Compensation Table · the one fiscal year held
In US dollars, as Verona Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$352,557
Bonus$0
Stock awards$6,783,563
Option awards$3,516,179
Non-equity incentive$155,833
Pension and deferred compensation$0
All other$13,800
Total$10,821,932

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Verona Pharma plc DEF 14A filed March 18, 2025, accession 0001104659-25-025050, and prior-year filings.

How this page was built: the Verona Pharma plc filed document, accession 0001104659-25-025050. Every figure is read from that document and cited to the page and table it appears in. Filed March 18, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU112,500$5,224,500—
RSU37,500$1,741,500—
Option300,000—$16.09

Per the Outstanding Equity Awards at Fiscal Year-End table in Verona Pharma plc's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Verona Pharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
David ZaccardelliPresident and Chief Executive Officer$19,456,473
Mark HahnChief Financial Officer$19,005,415
Andrew Fisher · this pageGeneral Counsel$10,821,932
Kathleen RickardChief Medical Officer$7,509,563
Claire PollFormer General Counsel$326,023

The full Verona Pharma compensation record

free company brief

This page is one person within Verona Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Verona Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Andrew Fisher's compensation dossier · One-time report. No refunds.